A 10-year-old male beagle was referred to us with seizure related to hypoglycemia and a large intraabdominal mass. Based on various types of imaging and a laparoscopic biopsy, the intraabdominal mass was diagnosed as a hepatocellular carcinoma (HCC) of the quadrate lobe. The hypoglycemia was suspected to be associated with the HCC. After lobectomy of the quadrate lobe was performed, blood glucose levels continued to increase to higher than normal values and sugar was detected in the urine. The dog was diagnosed as diabetes mellitus (DM) and was treated with insulin for over two years after the surgery. KEY WORDS: canine hepatocellular carcinoma, diabetes mellitus, hypoglycemia.
Hepatocellular carcinoma (HCC), the most common primary liver tumor in dogs [7, 8] , has previously been reported to be associated with hypoglycemia as paraneoplastic syndrome in a dog [6] . In general, hypoglycemia of non-islet cell tumors such as HCC is improved by resection and reappears after recurrence of a tumor [6] . This paper describes a canine case of HCC with hypoglycemia that became diabetes mellitus (DM) after surgical resection of the carcinoma.
A 10-year-old male beagle was referred to the Nihon University Animal Medical Center with seizures related to hypoglycemia and an intraabdominal mass. Physical examination revealed wasting (8.4 kg) , and a mass was palpated in the cranial portion of the abdominal cavity. There were no abnormal findings in neurological examinations. Complete blood counts and coagulation parameters were mostly within normal ranges. Blood biochemistry analysis revealed hypoglycemia (34.6 mg/dl), hypoalbuminemia (2.2 g/dl), low urea nitrogen (6.6 mg/dl), and high alanine aminotransferase (466 U/L), alkaline phosphatase (1504 U/L), and gamma glutamyl transpeptidase (47 U/L). The blood glucose level increased to 106.2 mg/dl after feeding. Fasting and postprandial serum bile acid levels were high (fasting, 55.9 µmol/l; postprandial, 166.0 µmol/l). Moreover, the serum insulin level was less than 1.0 µU/ml and the insulin-like growth factor I (IGF-I) concentration was abnormally low (1.35 nmol/l).
Radiography showed a mass in the midline of the abdomen ( Fig. 1A ) and no evidence of metastasis in the thorax. Ultrasonography revealed an enlarged and hypoechoic liver mass (Fig. 1B) , and computed tomography (CT) showed a liver mass that was not enhanced with contrast medium (Fig. 1C ). From the ultrasonography and CT findings, it was thought that the liver mass was confined to a quadrate liver lobe. Therefore, laparoscopy was performed to obtain biopsy samples from the liver mass. The laparoscopic findings showed that the quadrate liver lobe was enlarged and the pancreas appeared normal. Histopathological examination of needle biopsy specimens from several parts of the liver mass revealed HCC. From these results, hypoglycemia was suspected to be associated with HCC of the quadrate liver lobe. The dog's owner was advised to increase the number of times the dog was fed per day to prevent hypoglycemia. When we decided to perform surgical resection of the mass, the fasting blood glucose level of the dog was low (33.0 mg/ dl). Therefore, 20% glucose solution was administered intravenously before the operation and perioperative fluid therapy was maintained with solution containing 7.5% glucose (SOLITA-T No. 3G, Shimizu, Tokyo, Japan). Laparotomy was performed through a ventral midline. The quadrate lobe contained a discrete mass, and the other liver lobes, the lymph nodes, and the pancreas were grossly normal. The quadrate liver lobe was completely removed because the mass was confined to it and was not adhered to the gallbladder. The removed mass was 12 × 5 × 10 cm in size. Pathological examination revealed that normal liver architecture was lost and the hepatic cells were of various sizes. The nuclei of the neoplastic cells were hypochromatic and mitotic, and HCC was diagnosed.
The blood glucose level was high (203.8 mg/dl) just after surgery. The serum insulin level increased to 5.2 µU/ml.
Polyphagia and polydipsia appeared, and body weight decreased from 8.1 to 7.1 kg (Fig. 2 ). Dietary therapy (Hill's Prescription Diet r/d, Tokyo, Japan) was started for hyperglycemia, but blood glucose remained at a high level and the urine was positive for sugar. Therefore, the dog was diagnosed as having DM and received insulin therapy beginning seven days after surgery. The dog's hyperglycemia was controlled by intermediate-acting insulin (Novolin N, Novo Nordisk, Tokyo, Japan) ( Table 1) . At first, administration of insulin began at a dose of 0.3 U/kg twice daily, and the dosage was gradually increased to 0.8 U/kg twice daily while monitoring the blood glucose level and serum fructosamine concentration. Diabetic clinical signs such as polyphagia and polydipsia improved and body weight increased. The increased liver enzyme values and hypoalbuminemia before the operation improved gradually. On day 324, the serum bile acid levels returned to normal (fasting, 1.3 µmol/l; postprandial, 1.3 µmol/l). Radiography and ultrasonography were performed regularly to monitor for recurrence and metastasis. The dog lived as a result of insulin therapy and dietary control for more than two years after the operation.
Tumor-associated hypoglycemia is a common feature of insulinoma caused by insulin production by islet tumors in dogs [5] , and hypoglycemia may rarely arise in non-islet cell tumors, such as HCC, hepatoma, leiomyoma, leiomyosarcoma, melanoma and hemangiosarcoma in dogs [1-4, 6, 10] . In these non-islet cell tumors, the serum insulin concentration is low in dogs [1, 3, 8, 10] . Hypoglycemia is detected in these tumors, which are generally very large and found in the abdominal cavity. HCC might be the most common cancer that induces hypoglycemia in dogs [6] . Hypoglycemia with HCC has also been reported in humans and horses [9, 12] . In this particular case, we suspected that the hypoglycemia was due to HCC, since it was diagnosed by laparoscopic liver biopsy and the serum insulin concentration was low. Furthermore, the hypoglycemia disap-peared after the surgery.
It has been considered that the hypoglycemia associated with these tumors is caused by increased utilization of glucose by large tumors and the release of insulin-like peptides or growth factors. Particularly, this type of hypoglycemia has been associated recently with hypersecretion of insulinlike growth factor II (IGF-II) synthesized in the liver of humans and dogs [4, 11] . In a report that measured the serum IGF-I and II in a dog with hypoglycemia and a leiomyoma, IGF-I was significantly low while IGF-II was significantly high [4] . IGF-I was also low in our dog, but IGF-II could not be measured.
Hypoglycemia associated with non-islet cell tumors is improved generally by resection of the tumor [6] . Therefore, surgery is necessary to treat this type of hypoglycemia. After resection of the HCC, the blood glucose level of our case increased immediately. However, blood glucose level continued to increase. Subsequently, the dog was diagnosed with DM based on clinical signs such as polydipsia, polyphagia, hyperglycemia, and urine sugar. A previous canine case reportedly became hyperglycemia after surgery to remove non-islet cell tumors [6] . In this reported case, the dog was diagnosed with DM two days after resection of the HCC. The hyperglycemia was controlled by insulin for 1.5 months after the surgery, but the dog died from pyelonephritis. In our case, the DM was controlled by insulin therapy and a proper diet for more than two years.
In conclusion, resection of the HCC was successful in our dog with hypoglycemia. However, the dog developed DM and was treated with insulin for more than two years after the surgery. We believe that monitoring of blood glucose level and serum fructosamine concentration should be performed periodically.
